Volume 3.16 | Apr 28

Mammary Cell News 3.16 April 28, 2011
     In this issue: Science News | Current Publications | Industry News | Policy News | Events
Cell Therapy News on Facebook  Mammary Cell News on Twitter
Stem Cell Antigen-1 Enhances Tumorigenicity by Disruption of Growth Differentiation Factor-10–Dependent TGF-ß Signaling
To identify the mechanism underlying stem cell antigen (Sca)-1/Ly6A’s possible role in mammary tumorigenesis, Sca-1 expression was examined in Sca-1+/EGFP mice during carcinogenesis. [Proc Natl Acad Sci U S A]

Researchers Uncover New Potential Biomarker and Therapeutic Target for Aggressive Breast Cancer
In an analysis of more than 1,300 human breast tissue samples, a team of researchers discovered a possible role of the squamous cell carcinoma antigen in the progression of breast cancer. [Press release from Stony Brook University Medical Center discussing online prepublication in PLoS ONE]

CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal)


HER2 Overexpression Elicits a Pro-Inflammatory IL-6 Autocrine Signaling Loop that Is Critical for Tumorigenesis
In this study, scientists explore the relationship between HER2 and inflammation, comparing the effects of overexpressing wild-type or mutated inactive forms of HER2 in primary human breast cells. [Cancer Res]

Proangiogenic Factor PlGF Programs CD11b+ Myelomonocytes in Breast Cancer During Differentiation of Their Hematopoietic Progenitors
Researchers show that CD11b+ myelomonocytic cells develop proangiogenic properties during their differentiation from CD34+ hematopoietic progenitors and that placenta growth factor (PIGF) is critical in promoting this education. [Cancer Res]

Inhibition of PDE5 by Sulindac Sulfide Selectively Induces Apoptosis and Attenuates Oncogenic Wnt/Beta-Catenin Mediated Transcription in Human Breast Tumor Cells
Investigators show that sulindac sulfide can induce apoptosis of breast tumor cells, which predominantly rely on phosphodiesterase 5 (PDE5) for cGMP hydrolysis, but not normal mammary epithelial cells, which rely on PDE isozymes other than PDE5 for cGMP hydrolysis. [Cancer Prev Res]

mRNA and microRNA Expression Profiles in Circulating Tumor Cells and Primary Tumors of Metastatic Breast Cancer Patients
Scientists determined mRNA and microRNA expression of potentially circulating tumor cell-specific genes that are considered to be clinically relevant in breast cancer. [Clin Cancer Res]

Novel Measurements of Mammary Stem Cells in Human Umbilical Cord Blood as Prospective Predictors of Breast Cancer Susceptibility in Later Life
Investigators isolated mononuclear cells from umbilical cord blood of 170 singleton full-term pregnancies and determined, by reverse transcription polymerase chain reaction, the presence of genes of putative breast epithelial stem-cell/progenitor markers [including epithelial cell adhesion molecule, CD49f (a6-integrin), CD117 (c-kit receptor), CD24, and CD29 (ß1-integrin)]. [Ann Oncol]

ATM and p53 Regulate FOXM1 Expression Via E2F in Breast Cancer Epirubicin Treatment and Resistance
Researchers generated epirubicin resistant MCF-7 breast carcinoma (MCF-7-EPIR) cells and found FOXM1 protein levels to be higher in MCF-7-EPIR compared to MCF-7 cells, and that FOXM1 expression is down-regulated by epirubicin in MCF-7 but not in MCF-7-EPIR cells. [Mol Cancer Ther]

B7-H3 Silencing Increases Paclitaxel Sensitivity by Abrogating Jak2/Stat3 Phosphorylation
Investigators observed that silencing B7-H3, via stable shRNA or transient siRNA transfection, increased the sensitivity of multiple human breast cancer cell lines to paclitaxel as a result of enhanced drug-induced apoptosis. [Mol Cancer Ther]

Targeting GLI1 Expression in Human Inflammatory Breast Cancer Cells Enhances Apoptosis and Attenuates Migration
Data reveal a role for GLI1 in inflammatory breast cancer (IBC) cell proliferation, survival and migration, which supports the feasibility of targeting GLI1 as a novel therapeutic strategy for IBC patients. [Br J Cancer]

Elevated Expression of Squamous Cell Carcinoma Antigen (SCCA) Is Associated with Human Breast Carcinoma
This study shows that SCCA is associated with both advanced stage and high grade human breast carcinoma, and suggests the necessity to further explore the role of SCCA in breast cancer development and treatment. [PLoS One]

Molecular Profiling of a Lethal Tumor Microenvironment, as Defined by Stromal Caveolin-1 Status in Breast Cancers
To identify and characterize the signaling pathways activated in caveolin-1 negative tumor stroma, researchers performed gene expression profiling using laser microdissected breast cancer associated stroma. [Cell Cycle]


Use of Tamoxifen and Aromatase Inhibitors in a Large Population-Based Cohort of Women with Breast Cancer
Scientists constituted a cohort of 13?479 women with breast cancer who received at least one prescription of tamoxifen or aromatase inhibitors between 1998 and 2008, in the United Kingdom General Practice Research Database. [Br J Cancer]

Trastuzumab Beyond Progression in HER2-Positive Advanced Breast Cancer: The Royal Marsden Experience
Investigators have retrospectively evaluated the outcome of patients with HER-2-positive locally advanced or metastatic breast cancer who continued trastuzumab beyond disease progression, treated in their unit. [Br J Cancer]


Genomic Health Announces Launch of NCI RxPONDER Trial Utilizing Oncotype DX® in Women with Node-Positive Breast Cancer
Genomic Health, Inc. announced the launch of RxPONDER S1007 (Rx for Positive Node, Endocrine Responsive Breast Cancer), a clinical trial being led by SWOG, one of the largest National Cancer Institute (NCI) supported cancer cooperative groups. [Genomic Health, Inc. Press Release]

Halaven® Receives Approval in Japan for the Treatment of Inoperable and Recurrent Breast Cancer
Eisai Co., Ltd. announced that it has received approval to market its novel anticancer Halaven® Injection 1mg (eribulin mesylate) in Japan for the treatment of inoperable and recurrent breast cancer. [Eisai Co., Ltd Press Release]

Moffitt Cancer Center First in Tampa Bay to Offer a Single-Dose Radiation Treatment Alternative to Women with Early Breast Cancer
 Moffitt Cancer Center is the first in the Tampa Bay area to acquire the INTRABEAM® System, a new radiation platform that is designed to replace as many as six-and-a-half weeks of routine radiation therapy with a single 20- to 30-minute targeted radiation treatment. [Moffitt Cancer Center Press Release]


National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)


NEW Keystone Symposia: Changing Landscape of the Cancer Genome
June 20-25, 2011
Boston, United States

NEW Joint TuMIC – MRS – CF: New Concepts in Cancer Metastasis
June 25-28, 2011
Lisbon, Portugal

Visit our events page to see a complete list of events in the mammary cell community.


Lab Technologist – Human Embryonic and Induced Pluripotent Stem Cells (STEMCELL Technologies)

Post-doctoral Fellow (University of Texas Medical School at Houston) 

PhD Program – Tumor Cell Intrinsic Signaling Pathways that Regulate Immune Suppression (Lady Davis Institute of Medical Research)

Post-doctoral Fellow (New Jersey Medical School, University of Medicine and Dentistry of New Jersey)

Post-doctoral Research Associate (University of Wisconsin – Madison)

Post-doctoral Fellow (University of Texas Medical School at Houston)

Postdoctoral Fellowship on Tumor Microenvironment (Stanford University)

Recruit Top Talent

Reach more than 11,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Jobs are categorized regionally: United States, Canada, Europe, Asia Pacific

Visit here to post your career opportunities.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Mammary Cell News: Archives | Events | Contact Us